Combined platinum containing treatment in NSCLC

Lung Cancer

Volumn 38, Issue 3 SUPPL., 2002, Pages

  Crinò, Lucio ^a  

^a BELLARIA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOCETAXEL; GEFITINIB; GEMCITABINE; ISIS 3521; NAVELBINE; PACLITAXEL; PLATINUM; PROTEIN TYROSINE KINASE INHIBITOR;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DRUG RESEARCH; HUMAN; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0036895088     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0169-5002(02)00269-6     Document Type: Article

References (12)

1. Grenlee R.T., Murray T., Bolden S., Wings P.A. Cancer Statistic 2000. Ca Cancer J. Clin. 50:2000;7-33.
2. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br. Med. J. 311:1995;899-909.
3. ASCO. Clinical Practice guidelines for the treatment of unresectable non-small cell lung cancer. J Clin Oncol 1997; 15:2996-3018.
4. Bunn P.A., Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin. Cancer Res. 5:1998;1087-1100.
5. Sandler A.B., Nemunaitis J., Denham C., et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small cell lung cancer. J. Clin. Oncol. 18:2000;122-130.
6. Crinò L., Scagliotti G., Ricci S., et al. Gemcitabine and Cisplatin versus mitomycin, Ifosfamide and Cisplatin in advanced non-small cell lung cancer: a randomised phase III study of the Italian Lung Cancer Project. J. Clin. Oncol. 17:(11):1999;3522-3530.
7. Bonomi P., Kyung Mann, Fairclough D., et al. Comparison of survival and quality of life in advanced non-small cell lung cancer patients treated with two dose levels of Paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an easter cooperative oncology group trial. J. Clin. Oncol. 18:(3):2000;623-631.
8. Wozniak A.J., Crowley J.J., Balcerzak S.P., et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small cell lung cancer. A Southwest Oncology Group Study. J. Clin. Oncol. 16:1998;2459-2465.
9. Schiller J.H., Harrington D., Sandler A., et al. A randomised phase III trial of four chemotherapy regimens in advanced non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 19:2000;1a. (abstr 2).
10. Van Meerbeek J.P., Smith E.F., Lianes P., et al. A E.O.R.T.C. randomised phase III trial of three chemotherapy regimens in advanced non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 20:2001;308a. (abstr 1228).
11. Scagliotti G.V., De Marinis F., Rinaldi M., et al. Phase III randomised trial comparing three platinum-based doublets in advanced non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 20:2001;308a. (abstr 1227).
12. Kris M.G., Herbst R., Rischin D., et al. Objective regressions in non-small cell lung cancer patients treated in phase I trials of oral 2 D 1839 (Iressa) a selective tyrosine kinasl inhibitor that blocks the epidermal growth factor receptor (EGFR). Lung Cancer. 29:(1):2000;72. (abstr).